logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11352399 B1

PDFFull Text
Date of Patent:
Jun. 07, 2022

Filed:

Apr. 25, 2018

Peptide for toll-like receptor (tlr) inhibition and pharmaceutical composition comprising same

Applicant:

Genesen Co., Ltd., Seoul, KR;

Inventors:

Sang Dun Choi, Suwon-si, KR;

Hyuk Kwon Kwon, Pyeongtaek-si, KR;

Hyeon Jun Shin, Suwon-si, KR;

Xiang Ai Gui, Suwon-si, KR;

Assignee:

GENESEN CO., LTD., Seoul, KR;

Attorney:

Sughrue Mion, PLLC

Primary Examiner:

Bridget E Bunner

Int. Cl.
CPC ...
C07K 7/08 (2006.01); C07K 14/435 (2006.01); C07K 14/475 (2006.01); A61K 38/10 (2006.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); C07K 14/705 (2006.01); C07K 14/47 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); A61K 38/00 (2006.01); C07K 14/71 (2006.01);
U.S. Cl.
CPC ...
C07K 14/4703 (2013.01); A61K 38/10 (2013.01); A61K 38/1767 (2013.01); A61K 38/18 (2013.01); C07K 7/08 (2013.01); C07K 14/43581 (2013.01); C07K 14/475 (2013.01); C07K 14/705 (2013.01); C07K 16/241 (2013.01); C07K 16/249 (2013.01); C07K 16/2896 (2013.01); A61K 38/00 (2013.01); A61K 38/179 (2013.01); C07K 14/71 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01); C07K 2319/10 (2013.01); C07K 2319/32 (2013.01);
Abstract

The present invention relates to a fusion polypeptide that inhibits TLR1/2, TLR2/6, TLR7, TLR8 and TLR9 signaling pathways as well as Toll-like receptor 4 (TLR4) and TLR3, and a pharmaceutical composition for preventing or treating TLR pathway mediated diseases. The fusion peptide of the present invention has an excellent effect of inhibiting TLR4 and various TLR pathways and can be effectively used in preventing and treating various TLR pathway mediated diseases caused by the signaling pathways, such as autoimmune diseases, inflammatory diseases and degenerative neurological diseases, by inhibiting the TLR mediated immune responses.

Find Patent Forward Citations

Loading…